Liquidia Technologies Inc (NASDAQ:LQDA) – Wedbush increased their Q1 2019 earnings per share estimates for shares of Liquidia Technologies in a research report issued on Tuesday, March 26th, according to Zacks Investment Research. Wedbush analyst L. Moussatos now forecasts that the company will post earnings per share of ($0.45) for the quarter, up from their previous estimate of ($0.54). Wedbush currently has a “Buy” rating and a $49.00 target price on the stock. Wedbush also issued estimates for Liquidia Technologies’ Q2 2019 earnings at ($0.46) EPS, Q3 2019 earnings at ($0.46) EPS, FY2019 earnings at ($1.85) EPS, Q3 2020 earnings at ($0.62) EPS, Q4 2020 earnings at ($0.67) EPS, FY2020 earnings at ($2.30) EPS, FY2021 earnings at ($2.51) EPS, FY2022 earnings at ($1.07) EPS and FY2023 earnings at $1.63 EPS.
Liquidia Technologies (NASDAQ:LQDA) last issued its quarterly earnings results on Tuesday, February 26th. The company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.08.
Shares of LQDA stock traded up $0.05 during trading hours on Thursday, reaching $9.01. 242,405 shares of the company’s stock were exchanged, compared to its average volume of 191,808. Liquidia Technologies has a fifty-two week low of $8.33 and a fifty-two week high of $38.46. The firm has a market cap of $140.84 million and a PE ratio of -1.20. The company has a quick ratio of 4.85, a current ratio of 4.85 and a debt-to-equity ratio of 0.64.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Canaan Partners VIII LLC bought a new stake in Liquidia Technologies in the fourth quarter valued at $55,521,000. NEA Management Company LLC bought a new stake in Liquidia Technologies in the third quarter valued at $68,193,000. FMR LLC bought a new stake in Liquidia Technologies in the third quarter valued at $6,729,000. BlackRock Inc. bought a new stake in Liquidia Technologies in the third quarter valued at $5,924,000. Finally, Vanguard Group Inc bought a new stake in Liquidia Technologies in the third quarter valued at $4,263,000. Institutional investors and hedge funds own 46.84% of the company’s stock.
In other news, insider Kevin K. Gordon sold 11,322 shares of the business’s stock in a transaction that occurred on Tuesday, January 22nd. The stock was sold at an average price of $14.66, for a total transaction of $165,980.52. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Benjamin Maynor sold 2,187 shares of the business’s stock in a transaction that occurred on Thursday, February 28th. The shares were sold at an average price of $19.84, for a total value of $43,390.08. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 14,452 shares of company stock worth $225,496. 4.30% of the stock is currently owned by company insiders.
About Liquidia Technologies
Liquidia Technologies, Inc, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension.
Recommended Story: Liquidity
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Liquidia Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia Technologies and related companies with MarketBeat.com's FREE daily email newsletter.